AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10968599
Drug: Intravaginal clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal clindamycin cream
Trial: 8940218
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of conjugate heptavalent pneumococcal vaccine
Trial: 8940218
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of conjugate heptavalent pneumococcal vaccine
Trial: 8940218
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 23‐valent native polysaccharide vaccine
Trial: 8940218
Drug: Conjugate pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugate pneumococcal vaccine
Trial: 1347191
Drug: Sufentanil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (50 micrograms in 60 ml normal saline)
Trial: 1347191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bupivacaine 0.125% and sufentanil (50 micrograms in 60 ml bupivacaine 0.125%)
Trial: 3886154
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (825 mg initial dose followed by 550 mg if symptoms persisted)
Trial: 25092702
Drug: Dihydroartemisinin-piperaquine (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (180 mg dihydroartemisinin and 1,440 mg piperaquine administered as two consecutive daily doses once per month for a planned 4-month period)
Trial: 22538450
Drug: MMF-withdrawal (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF-withdrawal (target area under the time-concentration curve-cyclosporine: 3250 ng·hr/mL)
Trial: 22538450
Drug: CNI-withdrawal (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI-withdrawal (target area under the time-concentration curve-mycophenolic acid: 75 μg·hr/mL)
Trial: 17514671
Drug: Single-dose antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antimicrobial prophylaxis
Trial: 17514671
Drug: Multiple-dose antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose antimicrobial prophylaxis
Trial: 12032113
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (10 units)
Trial: 12032113
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (10 units)
Trial: 12032113
Drug: Intermediate-acting human
RxNorm normalized name: Intermediate-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-acting human insulin (bedtime injection)
Trial: 8016794
Drug: NCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCPAP treatment
Trial: 2739867
Drug: Oral VUEFFE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral VUEFFE (VF)
Trial: 4596491
Drug: Monovalent classical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent classical Ogawa vaccine
Trial: 4596491
Drug: Monovalent Inaba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent Inaba vaccine
Trial: 4596491
Drug: Monovalent El
RxNorm normalized name: hydroxypropyl cellulose (type EL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent El Tor vaccines (not specified)
Trial: 4596491
Drug: Monovalent classical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent classical Inaba vaccine
Trial: 30953333
Drug: roxadustat 50
RxNorm normalized name: Roxadustat 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxadustat 50 mg TIW
Trial: 30953333
Drug: roxadustat 70
RxNorm normalized name: Roxadustat 70 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxadustat 70 mg TIW
Trial: 30953333
Drug: roxadustat 100
RxNorm normalized name: Roxadustat 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxadustat 100 mg TIW
Trial: 28726169
Drug: Clonidine mucoadhesive
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine mucoadhesive buccal tablet (MBT) 50 and 100 µg
Trial: 28726169
Drug: Clonidine mucoadhesive
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine mucoadhesive buccal tablet (MBT)
Trial: 28726169
Drug: Reference clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference clonidine oral tablet (OT)
Trial: 19339887
Drug: Recent advancements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent advancements in RCC treatments
Trial: 11329233
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 5 mg/d for 13 days, for 9 months
Trial: 9416890
Drug: Captopril or
RxNorm normalized name: captopril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril or placebo (treatment arm)
Trial: 8495311
Drug: Cefazolin, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin, 500 mg every 8 hours for 24 hours
Trial: 3122113
Drug: Modified Goeckerman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Goeckerman treatment
Trial: 28103831
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment for BRVO
Trial: 28103831
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment for CRVO
Trial: 12508388
Drug: IV doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV doxycycline 300 mg/day for 14 days
Trial: 8952749
Drug: Strategies for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies for prevention and treatment of bone loss in lupus patients; specific interventions not detailed.
Trial: 8952749
Drug: Prevention of
RxNorm normalized name: Humanized IGG4 monoclonal antibody against toll-like receptor 2 for prevention of ischemia/reperfusion tissue injury
DrugBank: Tomaralimab (DB15415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention of steroid-induced bone loss; specific interventions not detailed.
Trial: 8952749
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of gonadal effects of cytotoxic agents; specific interventions not detailed.
Trial: 30869820
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy with a written checklist (Group II)
Trial: 30869820
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with a written checklist (Group IV)
Trial: 30869820
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment plus behavioral therapy without a checklist (Group III)
Trial: 30869820
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy as a written guideline (Group I)
Trial: 28003539
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (400 mg daily from 18-22 weeks of gestation to delivery)
Trial: 19954716
Drug: Gliclazide/metformin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide/metformin combination tablet (80/500 mg)
Trial: 19954716
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of gliclazide (80 mg) and metformin (500 mg) as individual tablets
Trial: 17355215
Drug: Novel compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel compounds under investigation for heart failure treatment
Trial: 10490152
Drug: Procaine with
RxNorm normalized name: penicillin G procaine with aluminum stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine with 0.3 mg epinephrine (EPI group)
Trial: 10490152
Drug: Procaine with
RxNorm normalized name: penicillin G procaine with aluminum stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine with 0.3 ml NaCl 0.9% (SALINE group)
Trial: 8944409
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg with fluvoxamine (mean dose 127 mg/day)
Trial: 1742482
Drug: GM-CSF (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (1.0 microgram/kg/d, increased as needed) with full-dose zidovudine (1,200 mg/d)
Trial: 6896183
Drug: Tolamolol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolamolol 200 mg
Trial: 26477496
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 10 mg daily ulipristal acetate for four repeated 12‐week treatment courses
Trial: 24249538
Drug: 6-monthly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-monthly follow-up
Trial: 24249538
Drug: 3-monthly follow-up
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-monthly follow-up
Trial: 8580277
Drug: Fluconazole oral
RxNorm normalized name: fluconazole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole oral suspension (200 mg loading dose followed by 100 mg q.d.s. for 2 weeks after symptom resolution)
Trial: 19292590
Drug: efavirenz-based triple
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz-based triple combination therapy
Trial: 11301568
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B complex capsules (fursulthiamine 50 mg, hydroxocobalamin 250 micrograms, pyridoxal phosphate 30 mg, and riboflavin 5 mg)
Trial: 3360270
Drug: Paracentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracentesis plus intravenous albumin infusion (40 g after each tap)
Trial: 3360270
Drug: Paracentesis without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracentesis without intravenous albumin infusion
Trial: 26331821
Drug: Icotinib hydrochloride
RxNorm normalized name: Nicotine
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib hydrochloride 150 mg every 12 hours
Trial: 26331821
Drug: Icotinib hydrochloride
RxNorm normalized name: Nicotine
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib hydrochloride 200 mg every 12 hours
Trial: 26331821
Drug: Icotinib hydrochloride
RxNorm normalized name: Nicotine
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib hydrochloride 125 mg every 8 hours
Trial: 26331821
Drug: Icotinib hydrochloride
RxNorm normalized name: Nicotine
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib hydrochloride (various doses)
Trial: 21959663
Drug: Anterior positioning
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior positioning splint therapy (group I)
Trial: 21959663
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy in addition to splint therapy (group III)
Trial: 18303526
Drug: Loop diuretics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics, nitrates, inotropes (dobutamine, milrinone)
Trial: 18303526
Drug: Vasoactive drugs
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive drugs
Trial: 2052631
Drug: Acu‐ES group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acu‐ES group (electrical stimulation applied to four antihypertensive acupuncture points)
Trial: 6315775
Drug: Naltrexone (opiate-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (opiate-receptor antagonist)
Trial: 29575717
Drug: Antifungal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal therapy (terbinafine, fluconazole, itraconazole, voriconazole, or posaconazole) for 4 to >12 weeks with standard bronchodilator and anti-inflammatory agents
Trial: 29575717
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without antifungals
Trial: 26223423
Drug: SLActive Bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLActive Bone level implant (Institut Straumann AG, Basel, Switzerland)
Trial: 26223423
Drug: CMI IS‐II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMI IS‐II active implant (Neobiotech Co., Seoul, Korea)
Trial: 17602086
Drug: gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1,000 mg/m2 (days 1 and 8; every 21 days)
Trial: 17602086
Drug: PLD 50
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 50 mg/m2 (day 1; every 28 days)
Trial: 14996349
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no lamivudine therapy)
Trial: 9509971
Drug: G‐CSF started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF started on day 0
Trial: 9509971
Drug: G‐CSF started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF started on day +3
Trial: 9509971
Drug: G‐CSF started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF started on day +5
Trial: 7800170
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg perazine
Trial: 27073832
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) therapy, 15 minutes of intermittent vibration, performed twice per week for three months.
Trial: 20363089
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of Addiction to Nicotine in Schizophrenia (TANS)
Trial: 20363089
Drug: Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Management (MM)
Trial: 18766258
Drug: PEGLip‐rFVIII‐FS reconstituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGLip‐rFVIII‐FS reconstituted with 4.2 mg/kg of pegylated liposomes
Trial: 18766258
Drug: PEGLip‐rFVIII‐FS reconstituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGLip‐rFVIII‐FS reconstituted with 12.6 mg/kg of pegylated liposomes
Trial: 18766258
Drug: PEGLip‐rFVIII‐FS reconstituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGLip‐rFVIII‐FS reconstituted with 22.1 mg/kg of pegylated liposomes
Trial: 15998278
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment with adjunctive doxycycline (100 mg/day for 15 days)
Trial: 15998278
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment without doxycycline
Trial: 12706919
Drug: B-type natriuretic
RxNorm normalized name: B-type natriuretic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-type natriuretic peptide (BNP) >80 pg/ml
Trial: 1944976
Drug: Postoperative anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative anti-platelet therapy with ASA and dipyridamole
Trial: 1944976
Drug: Postoperative anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative anti-platelet therapy with indobufene
Trial: 31868691
Drug: Basic care
RxNorm normalized name: Basic Care Miconazole KIT
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basic care of the face and mouth plus treatment as usual
Trial: 28586638
Drug: Paracetamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1,000 mg, Ibuprofen 400 mg, Codeine 60 mg
Trial: 28586638
Drug: Paracetamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1,000 mg, Ibuprofen 400 mg
Trial: 24569618
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg daily for 12 weeks
Trial: 17055685
Drug: Doxazosin mesylate
RxNorm normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin mesylate (4 mg single dose)
Trial: 9698717
Drug: Mebendazole 500
RxNorm normalized name: mebendazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 500 mg single-dose treatment
Trial: 9698717
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg single-dose treatment
Trial: 8550163
Drug: Conventional plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional plaster treatment
Trial: 20889882
Drug: Age less
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age less than 18 months (independent of treatment)
Trial: 19439966
Drug: 2.3 g
RxNorm normalized name: Urea 2.3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.3 g omega-3 fatty acids daily for 6 months
Trial: 11694151
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive treatment strategy (n = 1222)
Trial: 11694151
Drug: Noninvasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive treatment strategy (n = 1235)
Trial: 8275889
Drug: Phenothiazine (chlorpromazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenothiazine (chlorpromazine 350 mg)
Trial: 8275889
Drug: Butyrophenone (haloperidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butyrophenone (haloperidol 15 mg)
Trial: 8275889
Drug: Anticholinergic agents
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic agents (trihexiphenidyl, 5 mg)
Trial: 22743314
Drug: Inulin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (20 g/d, 3 times/d for 4 weeks)
Trial: 17373724
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of caffeine per day
Trial: 9689291
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of methyl nicotinate (vasodilator)
Trial: 2686425
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (200 mg every 12 hours, plus a daily extra placebo dose)
Trial: 30266711
Drug: S1 pedicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S1 pedicle screw with PMMA augmentation (group A)
Trial: 8566592
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of H. pylori eradication and acid suppression
Trial: 1937545
Drug: MCP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP plus oral lorazepam (1 mg/d)
Trial: 1937545
Drug: MCP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP (0.5 mg/kg 6 hourly i.v.)
Trial: 7035638
Drug: Intravenous alimentation
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alimentation with a solution containing carbohydrate as 50% glucose and 50% galactose
Trial: 27931142
Drug: Orafti® inulin‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orafti® inulin‐type fructans (2g daily for 6 weeks)
Trial: 19777799
Drug: Arginine supplementation
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine supplementation at 0.1 g/kg‐wt
Trial: 11407108
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa antagonists
Trial: 23656707
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (50 g available carbohydrate)
Trial: 23656707
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral glucose and white bread
Trial: 21942436
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg oral daily)
Trial: 16895950
Drug: T+DMPA (testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+DMPA (testosterone implant + depot medroxy progesterone acetate)
Trial: 16895950
Drug: T+DMPA+FSH (testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+DMPA+FSH (testosterone implant + depot medroxy progesterone acetate + follicle-stimulating hormone)
Trial: 16895950
Drug: T+DMPA+hCG (testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+DMPA+hCG (testosterone implant + depot medroxy progesterone acetate + human chorionic gonadotropin)